SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences informs about outcome of board meeting

15 Dec 2025 Evaluate

Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, RPG Life Sciences has informed that the Board of Directors of the Company, at its meeting held today, Monday, December 15, 2025, considered and unanimously approved the following: 1. Appointment of Amol Lone as the Chief Financial Officer and Key Managerial Personnel (KMP) of the Company effective from December 15, 2025, based on the recommendation of the Nomination and Remuneration Committee of the Company. 2. Incorporation of a new wholly owned subsidiary (‘WOS’) of the Company, in the name and style ‘RPG Active Pharma’ or such other name, as may be approved by the Ministry of Corporate Affairs, to be engaged, in the business of manufacture and marketing of active pharmaceutical ingredients (‘API’) and related pharmaceutical products. 3. Transfer of the API business of the Company to the WOS (upon its incorporation), as a going concern, pursuant to a business transfer agreement, and subject to receipt of applicable statutory and regulatory approvals. 4. Investment of an amount of up to Rs.105 crore in the WOS, in one or more tranches, for the purpose of capitalization, business operations and/or other related requirements. Necessary disclosures as required under the Listing Regulations read with applicable SEBI circulars shall be made as and when further investment is made in the WOS. The detailed disclosures as required under Regulation 30 read with Schedule III of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (‘SEBI Master Circular’), in respect of aforesaid matters are enclosed as Annexures I, II and III, respectively. The meeting commenced at 02:00 pm and concluded at 3.10 pm.

The above information is a part of company’s filings submitted to BSE.

RPG Life Sciences Share Price

1893.15 14.10 (0.75%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×